Biolinq’s CGM is clearing hurdles.
The news: The hardware maker raised $100M to transition its noninvasive glucose monitor from trials to commercialization.
Next-gen. Seeking US regulatory approval, Biolinq’s intradermal patch uses electrochemical sensors to analyze glucose levels directly below the skin.
Worn on the upper forearm, the device changes colors to deliver instantaneous feedback, while its platform factors activity and sleep data.
Designed for reliable tracking, multi-analyte sensing beyond glucose is in the pipeline.
Patched in. A breakthrough for diabetics, CGMs are also becoming a wellness tool.
Enjoying a duopoly, its two largest hardware manufacturers are reaping the rewards.
Abbott’s total CGM sales grew 22% in Q1, notching $1.7B. Finding success with its OTC patch Lingo—now selling on Amazon—highly engaged users check their data ~8x per day.
Running parallel, US market leader Dexcom partnered with Life Time to sell its consumer CGM direct to members while also investing in Oura.
New take. As Biolinq stacks funding, other hardware makers are deploying next-gen devices, with Roche landing EU approval for its AI CGM, Allez Health aiming to slash cost, and Liom (fka Spiden) landing $25M.
Punchline: Metabolic health is mainstream wellness, and CGMs tools of the trade.
